Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Eden Research Share Price
  4. Eden Research Share Regulatory News
  5. AIM Rule 17 Notification

Pin to quick picksEden Research Regulatory News (EDEN)

Eden Research Information

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
3.30    0.00 (0.00%)
Bid:
3.20
Ask:
3.40
Spread: 0.20 (6.25%)
Market Cap: £26.51m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

AIM Rule 17 Notification

24 Oct 2022 12:00

RNS Number : 8925D
Eden Research plc
24 October 2022
 

24 October 2022

 

Eden Research Plc

("Eden" or the "Company")

AIM Rule 17 Notification

Eden Research Plc (AIM: EDEN) the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces the following additional director disclosure provided pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules.

Richard Horsman, Non-executive director of Eden, is Non-executive chairman of Toople Plc ("Toople"). On 21 October 2022, the Directors of Toople appointed an administrator to preserve value for creditors.

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

 

 

01285 359 555

Cenkos Securities plc (Nominated advisor and broker)

Giles Balleny / Max Gould (corporate finance)Michael Johnson (sales)

 

 

020 7397 8900

Hawthorn Advisors (Financial PR)

Victoria AinsworthStephen Atkinson

 

eden@hawthornadvisors.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNUSARRUUURUAA
1234567
Date   Source Headline
27th May 20267:00 amRNSDirectorate change
28th Apr 20267:00 amRNSTrading Update
16th Apr 20262:59 pmRNSHolding(s) in Company
14th Apr 20264:30 pmRNSHolding(s) in Company
14th Apr 20263:31 pmRNSHolding(s) in Company
13th Apr 202611:31 amRNSHolding(s) in Company
10th Apr 20267:00 amRNSCompletion of Conditional Placing and TVR
8th Apr 202612:10 pmRNSSatisfaction of Conditions of Conditional Placing
2nd Apr 20267:00 amRNSThymolflex EPA approval
19th Feb 20263:59 pmRNSHolding(s) in Company
19th Feb 20261:29 pmRNSHolding(s) in Company
18th Feb 20269:40 amRNSResult of General Meeting and Total Voting Rights
5th Feb 20262:50 pmRNSResult of Retail Offer
2nd Feb 20261:01 pmRNSLaunch of Retail Offer
2nd Feb 202612:57 pmRNSProposed Placing and Subscription
9th Jan 20267:00 amRNSNovellus+ Regulatory Authorisation in Chile
7th Jan 20267:00 amRNSMevalone Label Extension in France
18th Dec 20257:00 amRNSAppointment of Syngenta as Distribution Partner
20th Nov 20257:00 amRNS3LOGY Label Extension in Italy
17th Nov 20257:00 amRNSEcovelex 2025 Approval in Italy
17th Sep 20259:45 amRNSDirector/PDMR Shareholdings
17th Sep 20258:36 amRNSDirector/PDMR Shareholdings
17th Sep 20257:00 amRNSHalf Yearly Report
15th Sep 20257:00 amRNSNotice of Results
18th Jun 20251:40 pmRNSResult of AGM
18th Jun 20257:00 amRNSAGM Statement
16th Jun 20257:00 amRNSEcovelex Partnership with Royal Holloway
27th May 20255:22 pmRNSNotice of AGM
13th May 20257:00 amRNSMevalone Approval in California - Powdery Mildew
9th May 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
6th May 202512:08 pmRNSHolding(s) in Company
6th May 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
10th Apr 20257:00 amRNSThymol Supply Agreement For Bee Health
1st Apr 202510:08 amRNSDirector/PDMR Shareholdings
24th Mar 20257:00 amRNSAppointment of Distribution Partner in Kenya
10th Mar 20257:00 amRNSAppointment of Joint Broker
5th Mar 202512:52 pmRNSDirector/PDMR Shareholding
5th Mar 20257:00 amRNSDirector/PDMR Shareholding
4th Mar 20252:13 pmRNSDirector/PDMR Shareholdings
6th Feb 20252:08 pmRNSDirector/PDMR Shareholding
5th Feb 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
28th Jan 202510:36 amRNSDirector/PDMR Shareholdings
13th Jan 20257:12 amRNSTrading Update
20th Dec 20247:00 amRNSRegulatory approval for Novellus+ in Mexico
16th Dec 20247:00 amRNSAppointment of Distributor in Austria
11th Dec 20247:00 amRNSMevalone Organic Input Registration in Germany
7th Nov 20247:01 amRNSTrading Update
7th Nov 20247:00 amRNSEcovelex Approval in Italy
8th Oct 202411:24 amRNSOTCQB exchange update
23rd Sep 20247:00 amRNSHalf yearly Report
1234567

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
0A40
0A40.L
LSE
0.00%
BGX
Sofix Ucits Etf
LSE
-0.69%
BOS
Bos Glb Hldgs
LSE
0.00%
EQLS
Equals Gp
LSE
0.00%
RCGH
Rc365 Holding
LSE
42.86%
Trending
MPL
Mercantile Ports & Logistics
LSE
26.92%
PREM
Premier African Minerals
LSE
-7.61%
AVCT
Avacta Group
LSE
-1.40%
FORG
Forgent
LSE
-5.26%
HEX
Helix Exploration
LSE
-0.67%